The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

“Biological age” may predict early colorectal cancer risk

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that one’s biological age, which can be higher than his or her chronological age – a concept called accelerated aging – may predict who’s at risk for developing colon polyps, a known risk factor for colorectal cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Wistar’s Nan Zhang and Noam Auslander receive $1.2M in biomedical research grants from V Foundation

Nan ZhangNoam AuslanderNan Zhang and Noam Auslander, the Wistar Institute assistant professors, have both received independent funding totaling $1.2 million over the next three years for cancer research projects from the V Foundation for Cancer Research. The grants are awarded to cancer researchers deemed “V Scholars” and allow Zhang and Auslander to pursue separate projects aimed at new strategies to improve the effectiveness of certain cancer therapies.
Clinical Roundup

Monoclonal antibody improves survival in cancer-associated hyper-inflammatory disorder

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.
Drugs & Targets

MD Anderson, AmMax Bio announce agreements to develop immunotherapy for MRD-positive cancers

The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
In Brief

Robert Schnoll named John H. Glick, MD Professor in Cancer Research at Penn Medicine

Robert Schnoll, Penn Medicine’s Abramson Cancer Center’s associate director for population science, was named the John H. Glick, MD Professor in Cancer Research. Schnoll is also the director of the Center for Interdisciplinary Research on Nicotine Addiction, a senior fellow in the Penn Center for Public Health, and co-director of the Community Research and Engagement Core at the Penn Center for AIDS Research.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account